<p>CanSino Biologics Inc's (CanSinoBIO) single-dose Covid-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in children aged 6-17, results from a small trial showed.</p>.<p>Researchers decided to lower the dosage after a few participants developed fever and headaches graded at level 2 severity - the second-lowest of four levels. In children, the lower dose triggered higher antibody levels than the dosage approved for use in adults in China, according to the peer-reviewed finding from a mid-stage trial.</p>.<p>The trial recruited 150 children and around 300 adults.</p>.<p>The results also showed that children given one lower dose had a stronger antibody response than adults who were given a booster shot 56 days after the first dose.</p>.<p>But the antibody readings did not show to what extent the vaccine can offer protection against Covid-19, researchers from a Chinese disease control agency, CanSinoBIO and other Chinese institutes cautioned in a paper.</p>.<p>CanSinoBIO's vaccine has not yet got the greenlight for children. China has approved three Covid-19 vaccines for use in children from the age of three: its two most commonly used shots from Sinovac and Sinopharm plus a third shot from Sinopharm. Vaccinations have yet to begin for those under 12.</p>.<p>The paper said the booster shot for CanSinoBIO's vaccine improved antibody responses in participants of different age groups, especially for older adults.</p>.<p>But cellular responses, another important part of human immune system, were not boosted by the second shot and researchers said a wider interval than 56 days should be considered.</p>.<p><strong>Check out DH's latest videos</strong></p>
<p>CanSino Biologics Inc's (CanSinoBIO) single-dose Covid-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in children aged 6-17, results from a small trial showed.</p>.<p>Researchers decided to lower the dosage after a few participants developed fever and headaches graded at level 2 severity - the second-lowest of four levels. In children, the lower dose triggered higher antibody levels than the dosage approved for use in adults in China, according to the peer-reviewed finding from a mid-stage trial.</p>.<p>The trial recruited 150 children and around 300 adults.</p>.<p>The results also showed that children given one lower dose had a stronger antibody response than adults who were given a booster shot 56 days after the first dose.</p>.<p>But the antibody readings did not show to what extent the vaccine can offer protection against Covid-19, researchers from a Chinese disease control agency, CanSinoBIO and other Chinese institutes cautioned in a paper.</p>.<p>CanSinoBIO's vaccine has not yet got the greenlight for children. China has approved three Covid-19 vaccines for use in children from the age of three: its two most commonly used shots from Sinovac and Sinopharm plus a third shot from Sinopharm. Vaccinations have yet to begin for those under 12.</p>.<p>The paper said the booster shot for CanSinoBIO's vaccine improved antibody responses in participants of different age groups, especially for older adults.</p>.<p>But cellular responses, another important part of human immune system, were not boosted by the second shot and researchers said a wider interval than 56 days should be considered.</p>.<p><strong>Check out DH's latest videos</strong></p>